Especially with 150 cannabinoids and 200 terpenes giving us 30,000 possible combinations just on chemo alone.
Types 1-6 work defining by cannabinoid ratios, the chemotype. “OG x NL5” is often how genotype is expressed. And phenotype uses Narrow Leaf Drug, Broad Leaf Drug, Narrow Leaf Hemp, and Broad Leaf Hemp taxa.
But not every stakeholder cares about each, for instance a patient would focus on chemical content, including terpenes, and not necessarily care about the pheno.
And then there’s degradation over time of products on the shelf. And in an acid matrix CBD will be stony. Plus variations in production resulting in different decarb rates product to product, thus slightly different ratios in each. Quality Assurance is a journey, not a destination.